Anti-vascular endothelial growth factor therapy in uveitis: Bridging inflammation and vascular pathology
Abstract
Anti-vascular endothelial growth factor (VEGF) therapy has emerged as an important adjunct in the management of uveitis, particularly for complications driven by vascular permeability and ischemia, such as uveitic macular edema, inflammatory choroidal neovascularization, and retinal neovascularization (RNV). By directly neutralizing VEGF, these agents offer rapid anatomical improvement and visual stabilization, especially in patients who are steroid-intolerant or present with refractory disease. Although current evidence is largely derived from small series and observational data, the accumulating clinical experience highlights a meaningful therapeutic role for anti-VEGF agents when used in conjunction with appropriate immunosuppression or antimicrobial therapy. Emerging roles extend to inflammatory RNV, tubercular granulomas, and serous retinal detachment. However, sterile intraocular inflammation, vasculitis, and rare endophthalmitis remain important safety concerns. Evolving delivery strategies, including sustained-release formulations, posterior sub-Tenon and exploratory topical approaches, may further expand their utility while improving safety. This review synthesizes current evidence, mechanistic insights, and future directions for integrating anti-VEGF therapy in uveitis care.
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.